Fontan-associated Protein Losing Enteropathy and Heart Transplant: A Pediatric Heart Transplant Study Analysis

Cumulative Effect of Preoperative Risk Factors on Mortality After Pediatric Heart Transplantation

“…Some singlecenter studies have demonstrated survival differences after HT in Fontan patients depending on the specific indication for HT. Patients with preserved ejection fraction (ie, patients with PLE or plastic bronchitis) have worse outcomes than those with impaired ejection fraction [20,21]; however, data on this subject are conflicting [22]. The absence of Fontan physiology as a risk factor in the current study could be related to the relatively equal distribution of indications for HT.…”

Current Topics and Controversies in Pediatric Heart Transplantation: Proceedings of the Pediatric Heart Transplantation Summit 2017

“…In Fontan lymphatic failure diseases, transplant has been shown to be a viable and even curative procedure. 47 Thus, symptomatic protein-losing enteropathy (PLE) refractory to typical treatments or PLE with growth failure should be indications for transplant referral.…”

Challenges of Cardiac Transplantation Following the Fontan Procedure

“…No differences were detected in posttransplant survival ( P = .12; Figure 5), time to rejection ( P = .85), and time to first major infection ( P = .47). 36 Furthermore, resolution of PLE should be expected posttransplantation, with several studies reporting greater than 90% chance of resolution. 36,37…”

“…36 Furthermore, resolution of PLE should be expected posttransplantation, with several studies reporting greater than 90% chance of resolution. 36,37…”

“…Kaplan-Meier survival depiction and 70% CL stratified by the presence or absence of protein-losing enteropathy (PLE) after Fontan. Reproduced with permission from Schumacher et al 36 PHTS indicates Pediatric Heart Transplant Study; PLE, protein-losing enteropathy.…”